We are live on ! Find out more
BLRX

BioLineRX

34 hedge funds and large institutions have $15.7M invested in BioLineRX in 2018 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 5 increasing their positions, 7 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

800% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 1

31% more funds holding

Funds holding: 2634 (+8)

0.01% less ownership

Funds ownership: 0.06%0.05% (-0.01%)

29% less repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 7

62% less capital invested

Capital invested by funds: $41M → $15.7M (-$25.2M)

Holders
34
Holders Change
+8
Holders Change %
+30.77%
% of All Funds
0.76%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
9
Increased
5
Reduced
7
Closed
1
Calls
Puts
Net Calls
Net Calls Change

BLRX Hedge Fund Activity: Q4 2018 in Review

34 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in BioLineRX (BLRX) for Q4 2018, worth a combined $15.7M — down 62% from $41M a quarter earlier.

Buyers outnumbered sellers: 9 funds opened new BLRX positions and 1 closed out — a net gain of 8 holders — while 5 added to existing stakes and 7 trimmed.

The largest buyer was ETF Managers Group, adding an estimated $134K. The largest seller was Senvest Management, cutting an estimated $2.35M.

  • 34 institutional investors held BioLineRX (BLRX) as of Q4 2018, up from 26 in Q3 2018.
  • Funds reported $15.7M of BioLineRX stock for Q4 2018, down 62% quarter-over-quarter.
  • 9 funds opened new BioLineRX positions in Q4 2018 and 1 closed out, a net change of +8 holders.
  • The largest BioLineRX buyer in Q4 2018 was ETF Managers Group, an estimated $134K added.
  • The largest BioLineRX seller in Q4 2018 was Senvest Management, an estimated $2.35M sold.

Based on aggregated 13F filings for Q4 2018.